News

Filter

Current filters:

BioLineRx

Catalyst-rich period ahead for key trial results from BioLineRx

09-12-2013

Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…

Anti-viralsBioLineRxBL-1040BL-8020BL-8040Cardio-vascularFinancialOncologyPharmaceuticalResearch

BioLineRx collaborates with Chinese firm on hep C drug BL-8030

11-06-2013

Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

BioLineRx in-licenses BL-8020, an oral hepatitis C treatment

26-01-2012

Israeli biopharma company BioLineRx (Nasdaq: BLRX) says it has signed a worldwide, exclusive license…

Anti-viralsBioLineRxGenoscienceLicensingPharmaceutical

BioLineRx inks deal with Compugen

14-12-2011

Israeli biopharma company BioLineRx (TASE: BLRX) has entered into a collaboration with fellow Israel-based…

BioLineRxBiotechnologyCardio-vascularCompugenInflammatory diseasesLicensingOncologyPharmaceuticalResearch

Ramius makes unsolicited, 60% premium offer to buy Cypress Bioscience for $4.00 per share in cash

20-07-2010

Shares of USA-based Cypress Biosciences rocketed up almost 40% to $3.41 on news of a takeover offer yesterday…

BioLineRxBiotechnologyCypress BioscienceMergers & AcquisitionsPharmaceuticalRamius

Cypress Bioscience in-licenses novel antipsychotic from BioLineRx for potential $365 million

21-06-2010

San Diego, USA-based Cypress Bioscience has entered into an exclusive North American licensing deal for…

BioLineRxCypress BioscienceLicensingNeurologicalPharmaceutical

COMPANY SPOTLIGHT

Menarini

Back to top